Merck KGaA Inks Up to USD 3 Billion AI-Driven Drug Discovery Deal with Valo Health
Merck KGaA has entered into a major strategic collaboration with Valo Health to use Valo’s AI-powered human causal biology platform for discovering and developing new treatments for Parkinson’s disease and related disorders.
Merck KGaA | 21/11/2025 | By Darshana | 432
Skyhawk Therapeutics has entered a strategic research collaboration worth over USD 2 billion with Merck KGaA, Darmstadt, Germany to develop novel RNA-targeting small molecules for neurological disorders.
Merck KGaA | 19/08/2025 | By Mrinmoy Dey | 234
Merck KGaA Adopts Quris-AI's Bio-AI Platform for its Drug Development Pipeline
Quris-AI’s drug safety prediction platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug- induced toxicities better.
Merck KGaA | 09/01/2025 | By Aishwarya | 587
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy